FSSAI takes action against Nestle for 'false' baby food tags
Source Entity
ANUJA JAISWAL AND RUPALI MUKHERJEE
The FSSAI has launched three legal cases against Nestlé India regarding misleading promotional claims for infant formula and non-compliant biotin levels. While the regulator cites regulatory violations, Nestlé India maintains that its products remain fully compliant with applicable safety standards.
FSSAI Challenges Nestlé Over Infant Nutrition Standards
The Food Safety and Standards Authority of India (FSSAI) has formally initiated three separate legal cases against Nestlé India, marking a significant escalation in the regulatory oversight of the infant nutrition sector. The action stems from an investigation into the promotional claims of specific infant formula products and the chemical composition of others, highlighting the stringent requirements governing products designed for the most vulnerable consumers.
Scrutiny of Promotional Claims
Two of the three cases center on marketing practices observed on e-commerce platforms. Specifically, the FSSAI has flagged promotional material for NAN Excella Pro Stage 1 and Lactogen Pro 1. The regulator is questioning the veracity of claims regarding '5 HMOs' (human milk oligosaccharides) and the assertion that the 'whey protein' in Lactogen Pro 1 is 'easy to digest.' These cases underscore the FSSAI's intent to curb potentially misleading marketing that could influence parental choices regarding infant nutrition.
Concerns Over Nutritional Composition
Beyond marketing, the third case addresses a technical failure in product quality. A sample of Nestlé’s follow-up formula was tested and found to contain non-conforming levels of biotin. Biotin is a critical micronutrient required for metabolic processes, and the FSSAI’s finding suggests that the product did not meet the nutritional profile mandated by Indian safety standards, potentially posing a risk to the standardized dietary intake expected from such formulas.
Regulatory Enforcement and Compliance
This enforcement action follows a proactive examination by the FSSAI of products available in the digital marketplace. By targeting both the 'Unit I' and 'Unit II' facilities of Nestlé India, the authority is casting a wide net to ensure systemic compliance across the company’s manufacturing chain. This reflects a broader trend of Indian regulators moving toward more aggressive post-market surveillance of processed food and health products.
Corporate Stance and Future Implications
In response to these developments, a Nestlé India spokesperson has publicly affirmed that their products remain fully compliant with all applicable national regulations. This defense sets the stage for a legal contest between the food giant and the regulator. The outcome of these cases will likely establish a precedent for how infant formula manufacturers communicate nutritional benefits and maintain chemical consistency in the Indian market.
Conclusion
The confrontation between the FSSAI and Nestlé serves as a critical reminder of the high stakes involved in the infant nutrition industry. As regulatory scrutiny intensifies, companies must balance aggressive marketing strategies with the absolute necessity of meeting precise nutritional standards. The resolution of these three cases will be closely monitored by industry stakeholders and consumer advocacy groups alike, as it will define the boundaries of acceptable health claims and quality control for infant products in India.